Onpattro

Chemical Namepatisiran
Dosage FormInjection (intraveneous; 10 mg/5 mL (2 mg/mL))
Drug ClassOligonucleotides
SystemCardiovascular, Musculoskeletal, Skin, Blood, Urinary, Nervous
CompanyAlnylam Pharmaceuticals Inc.
Approval Year2018

Indication

  • To treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Onpattro (Patisiran) Prescribing Information2018Alnylam Pharmaceuticals Inc., Cambridge, MA